STOCK TITAN

Livanova Plc - LIVN STOCK NEWS

Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.

Overview of LivaNova Plc

LivaNova Plc is a globally recognized medical technology company renowned for its advanced cardiopulmonary solutions and neuromodulation devices. With a history spanning nearly five decades, the company provides essential medical products that address critical healthcare challenges, enhancing outcomes for patients and offering innovative solutions for healthcare professionals.

Core Business and Product Divisions

At the heart of LivaNova's operations is a dedication to developing breakthrough treatments within two major segments. The cardiopulmonary solutions division delivers sophisticated devices such as heart-lung machines and oxygenation equipment that support complex medical procedures. Additionally, its neuromodulation segment focuses on cutting-edge devices designed to treat conditions such as treatment-resistant epilepsy and depression, thereby offering a unique blend of technological innovation and therapeutic efficacy.

Historical Context and Strategic Merger

LivaNova was born from the merger of two influential companies, a union between a US-based firm and an Italian entity. This strategic merger allowed the company to consolidate expertise and divest non-core areas such as cardiac rhythm management and heart valve systems. Today, this refined focus enables LivaNova to concentrate resources on areas where it can deliver both clinical and economic value.

Global Footprint and Market Positioning

Headquartered in the UK, LivaNova operates in more than 100 countries, underpinning its stature as a major player in the global medical technology landscape. The company derives a significant portion of its revenue from the US market, complemented by a strong presence in Europe and other international regions. This diversified geographic reach ensures that LivaNova remains resilient and adaptable in a dynamic global healthcare arena.

Innovation, Expertise, and Industry Insight

With a product portfolio that highlights the integration of innovation and deep sector knowledge, LivaNova stands out through its commitment to enhancing patient outcomes and supporting healthcare infrastructure. The company’s strategic focus on advanced circulatory support and neuromodulation reflects its understanding of the evolving challenges within modern medicine. By consistently leveraging its extensive experience and technological acumen, LivaNova not only responds to current market needs but also anticipates the demands of evolving clinical practices.

Operational Excellence and Commitment to Patient Care

LivaNova is dedicated to delivering products that are both clinically effective and economically viable. Its operations are driven by robust research and development, ensuring that every product meets rigorous quality and safety standards. The company’s neutrally balanced approach makes it a key contributor to healthcare systems worldwide, striving to improve patient care without favoring any one market or region.

Competitive Landscape and Strategic Differentiators

  • Focused Specialization: Concentration on high-impact areas like cardiopulmonary and neuromodulation devices where technological breakthroughs are most needed.
  • Global Reach: Extensive international presence that facilitates diversified revenue streams and responsiveness to varied market demands.
  • Merged Expertise: The combination of experiences from its founding companies provides a unique blend of US and European market insight, strengthening its product development and service delivery.

Conclusion

In summary, LivaNova Plc exemplifies a robust commitment to medical technology innovation and patient-centric solutions. Its refined focus on advanced treatment modalities, supported by an international operational framework and deep industry expertise, makes it a noteworthy entity within the global healthcare ecosystem. The company continues to set benchmarks in clinical efficacy and operational excellence, sustaining its role as an influential player in critical care segments.

Rhea-AI Summary

LivaNova PLC (Nasdaq: LIVN) will host a conference call to discuss its first-quarter 2023 results on May 3, 2023, at 1 p.m. London time (8 a.m. Eastern Time). The results will be released prior to the call, and a live audiocast will be accessible on the company's website. Investors can join by dialing the respective numbers for the U.S. and international callers. The company has nearly five decades of experience in the medical technology sector and operates in over 100 countries. A replay of the call will be available on their website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) has received FDA 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM), marking the start of its commercial launch in the U.S. The company also secured approvals from Health Canada and the Japanese PMDA, initiating a broader commercial release in Europe. The Essenz Perfusion System enhances clinical workflows and patient care during cardiopulmonary bypass (CPB) procedures, featuring reliable technology based on the LivaNova S5™ HLM. Key benefits include individualized patient care, user-friendly interfaces, and robust support worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (Nasdaq: LIVN) has announced that its Chief Executive Officer, Damien McDonald, will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The event is scheduled for 9 a.m. Eastern Time on Thursday, March 16. Interested parties can register for the webcast through www.livanova.com/events, with a replay available on the company's website for 90 days after the presentation. LivaNova is a global medical technology company dedicated to improving patient outcomes with innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
conferences
Rhea-AI Summary

LivaNova PLC (Nasdaq: LIVN) reported Q4 2022 revenue of $274.9 million, up 1.8% year-over-year, with adjusted diluted EPS at $0.81. For full-year 2022, revenue was $1.02 billion, down 1.3%, but showed a 2.3% rise when excluding the Heart Valve business divested in 2021. The Cardiopulmonary segment grew 10.5%, driven by increased cardiac surgeries. However, Advanced Circulatory Support revenue fell 29.1% due to fewer ECMO treatments. Looking ahead, LivaNova expects 2023 revenue growth of 3-5% and adjusted diluted EPS between $2.45 and $2.65. The company also ceased its heart failure clinical study due to disappointing data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.92%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (Nasdaq: LIVN) has initiated a limited commercial release of the Essenz™ Perfusion System in select European centers, following positive clinical experiences at Catharina Hospital in the Netherlands and San Donato Hospital in Italy. The innovative system integrates a next-generation heart-lung machine and a patient monitor, focusing on providing data-driven, personalized support during cardiopulmonary bypass procedures. Both components have received CE Mark, with further regulatory approvals pending in key regions. The release marks a significant advance in perfusion technology, emphasizing safety and operational flexibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News
Rhea-AI Summary

LivaNova PLC has launched the SenTiva DUO, an implantable pulse generator designed to provide VNS Therapy for drug-resistant epilepsy. This new device features a dual-pin header, allowing existing patients with dual-pin systems to upgrade without lead revision. It maintains the therapeutic advantages of the original SenTiva, including automatic seizure response and programmable therapy options. The device has received 510(k) clearance from the U.S. FDA and is now available in the U.S. market, aiming to enhance patient care for those requiring advanced epilepsy treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
none
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) will host a conference call on February 22, 2023, at 1 p.m. London time to discuss its fourth-quarter and full-year 2022 results. The results will be released prior to the call. The audiocast can be accessed via www.livanova.com/events. Participants can join via telephone by calling +1 844 200 6205 (U.S.) or +1 929 526 1599 (international), with access code 041577. A replay will be available for 90 days after the call. LivaNova is a global leader in medical technology, focused on delivering innovative solutions for patients and healthcare systems worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) has received a close-out letter from the FDA regarding the Warning Letter issued on December 29, 2015, related to its Munich facility and 3T Heater-Cooler device. This closure signifies the successful implementation of corrective actions by LivaNova. CEO Damien McDonald expressed gratitude for the FDA's collaboration and the efforts of the LivaNova team during this process. The company emphasized its commitment to quality and safety in its operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) announced its participation in the American Epilepsy Society 2022 Annual Meeting, taking place from December 2-6 in Nashville, Tennessee. The company will showcase seven scientific posters focused on advancing neuromodulation and improving treatment for drug-resistant epilepsy. Dr. Bryan Olin emphasized the company's commitment to enhancing patients' quality of life. Attendees will have the opportunity to engage with presenters about the research findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
conferences
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) has received 510(k) clearance from the FDA for its LifeSPARC system, enhancing access to extracorporeal membrane oxygenation (ECMO) for hospitals. This new clearance allows ECMO use beyond six hours for patients in acute respiratory or cardiopulmonary failure, including those affected by COVID-19. LifeSPARC aims to simplify ECMO with a user-friendly design, making it suitable for healthcare facilities of all sizes. The company has a strong track record of 100% customer response to recent updates following a recall.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none

FAQ

What is the current stock price of Livanova Plc (LIVN)?

The current stock price of Livanova Plc (LIVN) is $39.17 as of March 7, 2025.

What is the market cap of Livanova Plc (LIVN)?

The market cap of Livanova Plc (LIVN) is approximately 2.2B.

What does LivaNova Plc specialize in?

LivaNova Plc specializes in advanced medical technologies primarily focused on cardiopulmonary solutions and neuromodulation devices. These products are designed to improve patient outcomes and support healthcare systems globally.

How does LivaNova generate revenue?

The company generates revenue by developing and selling sophisticated medical devices and providing related services. Its diversified approach spans key international markets, ensuring a balanced revenue stream from multiple regions.

What are the core product segments at LivaNova?

LivaNova focuses on two core segments: cardiopulmonary solutions, which include heart-lung machines and oxygenation equipment, and neuromodulation devices used in the treatment of conditions like treatment-resistant epilepsy and depression.

How did the merger contribute to LivaNova's current business model?

The merger of a US-based company with an Italian firm allowed LivaNova to consolidate expertise and focus on high-impact areas. This strategic move enabled the company to divest non-core areas and concentrate on advanced circulatory support and neuromodulation.

In which regions does LivaNova operate?

LivaNova has a significant global presence, operating in more than 100 countries. The company derives a substantial portion of its revenue from the US market, with a strong footprint in Europe and other international regions.

What differentiates LivaNova from its competitors?

LivaNova differentiates itself through its focused specialization in critical areas such as cardiopulmonary and neuromodulation technologies. Its merger heritage, global operational framework, and commitment to innovation further enhance its competitive position.

How does LivaNova maintain quality and safety in its products?

The company maintains quality and safety in its products by adhering to stringent research and development practices and rigorous testing protocols. Continuous innovation and operational excellence are central to its approach to meet high industry standards.

What is LivaNova's main contribution to healthcare?

LivaNova contributes to healthcare by providing advanced medical technologies that improve patient care and support clinical practices. Its products are designed to offer both clinical efficacy and economic value, addressing critical challenges in modern medicine.
Livanova Plc

Nasdaq:LIVN

LIVN Rankings

LIVN Stock Data

2.17B
53.95M
0.33%
102.28%
4.21%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United Kingdom
LONDON